ArticleEuropean journal of nuclear medicine and molecular imaging2025
Utility of
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03392181 (PET/MRI for the Staging of Newly Diagnosed Prostate Cancer), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
Who cites it
8 citing papers in PubMed.
- Lymph node dissection based on 18F-PSMA PET/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study.Prostate cancer and prostatic diseases · 2026Trial
- Deep learning algorithm assisting diagnosis of prostate cancer extracapsular extension based on [Prostate cancer and prostatic diseases · 2026Article
- Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.Prostate cancer and prostatic diseases · 2026Article
- Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy.European journal of nuclear medicine and molecular imaging · 2026Article
- Biparametric magnetic resonance imaging-based radiomics model can improve the detection of dense and sparse prostate cancers.Quantitative imaging in medicine and surgery · 2025Article
- Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology.International journal of molecular sciences · 2025Review
- Semiquantitative Analysis in PET/CT Imaging of Prostate Cancer.Journal of clinical medicine · 2025Review
- Does total lesion prostate-specific membrane antigen (PSMA) activity onBJUI compass · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposePSMA PET offers the potential for improved local staging prior to radical prostatectomy (RP). We evaluated PSMA PET versus mpMRI for local and nodal staging for patients with localized NCCN high or very high risk prostate cancer undergoing RP.
methodsA prospective single center pilot study was conducted from 9/2018 to 6/2022. Patients underwent both mpMRI and
resultsAt RP, 79% (38/48) had EPE, 31% had SVI, and 31% had LNI. At the patient level for EPE, PSMA PET had similar sensitivity (65.8% vs. 84.2%, respectively, P = 0.07) but higher specificity (80% vs. 40%, P = 0.045) compared to mpMRI, respectively. For SVI, PSMA PET had lower sensitivity (62.5% vs. 87.5%, P = 0.046) and similar specificity (87.5% vs. 90.6%, P = 0.56). For side-specific LNI, PSMA PET had higher sensitivity (50% vs. 25%, P = 0.03) and similar specificity (96.1% vs. 94.7%, P = 0.71) compared to mpMRI.
conclusionPSMA PET offers higher specificity for EPE and higher sensitivity for LNI compared to mpMRI. PSMA PET may improve overall surgical planning, and may be combined with diagnostic mpMRI and clinicopathological variables through nomograms to further predict EPE, SVI, or LNI. CLINICAL
trial registrationNCT03392181 https://clinicaltrials.gov/study/NCT03392181 .
Indexed as
Identifiers
39928105What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.